Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsMing Yi, Kongming Wu|Molecular Cancer|2022Cited by 1.4k
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentMing Yi, Anping Li|Molecular Cancer|2019Cited by 604
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumorsMing Yi, Kongming Wu, Mengke Niu et al.|Journal of Hematology & Oncology|2022Cited by 178
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancersMing Yi, Kongming Wu|Journal of Hematology & Oncology|2021Cited by 176
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancerMing Yi, Kongming Wu|Journal for ImmunoTherapy of Cancer|2022Cited by 153